catalyst · primary record
31-valent pneumococcal conjugate vaccine + Seasonal Influenza Vaccine (SIV) (Flublok) + Placebo
Phase readout · 2027-03-01 · Pneumococcal Disease
| Company | Vaxcyte, Inc. |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT07365826 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:55.994Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Vaxcyte, Inc.:31-valent pneumococcal conjugate vaccine + Seasonal Influenza Vaccine (SIV) (Flublok) + Placebo:2027-03-01:P3 primary completion · NCT07365826
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.